表紙
市場調查報告書

尿失禁:開發中產品分析

Urinary Incontinence - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 232798
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
尿失禁:開發中產品分析 Urinary Incontinence - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 80 Pages
簡介

尿失禁是由於膀胱失去控制造成的狀態。尿失禁的症狀有緊張性尿失禁,皮疹和其他皮膚疾病,高齡化,過重,抽煙,腎臟疾病等是可能發病的要素。主要尿失禁治療藥有抗膽鹼促效劑,局部雌激素等。

本報告提供尿失禁治療藥的開發趨勢調查,提供您開發平台各階段的產品概要,主要企業藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

尿失禁概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

尿失禁:企業開發中的治療藥

尿失禁:大學/機關研究中的治療藥

尿失禁:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

尿失禁:企業開發中的產品

尿失禁:大學/機關研究中的產品

尿失禁治療藥的開發企業

  • Allergan Plc
  • Astellas Pharma Inc.
  • Celogos
  • Cook MyoSite Incorporated
  • Evotec AG
  • FemmePharma Global Healthcare, Inc.
  • Innovacell Biotechnologie AG
  • TheraVida, Inc.

尿失禁:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (mirabegron + solifenacin succinate)
  • ASP-2205
  • ASP-5633
  • Cell Therapy for Urinary Incontinence
  • ICES-13
  • oxybutynin hydrochloride
  • Prof-003
  • RCD-1
  • senrebotase
  • Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence
  • Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases
  • THVD-201
  • THVD-202

尿失禁:最近的開發平台趨勢

尿失禁:暫停中的計劃

尿失禁:開發中止的產品

尿失禁:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12384IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2020, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 5, 3 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Urinary Incontinence - Overview
  • Urinary Incontinence - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Urinary Incontinence - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Urinary Incontinence - Companies Involved in Therapeutics Development
  • Allergan Ltd
  • Cook MyoSite Inc
  • Crystec Ltd
  • FemmePharma Global Healthcare Inc
  • Innovacell Biotechnologie AG
  • Ixaltis
  • Johnson & Johnson
  • Ningbo Xijian Pharmaceutical Technology Co Ltd
  • Outpost Medicine Ltd
  • Pfizer Inc
  • Profem GmbH
  • Revance Therapeutics Inc
  • Saniona AB
  • Taiho Pharmaceutical Co Ltd
  • Urinary Incontinence - Drug Profiles
  • Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy for Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Urinary Incontinence - Dormant Projects
  • Urinary Incontinence - Discontinued Products
  • Urinary Incontinence - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Urinary Incontinence, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Urinary Incontinence - Pipeline by Allergan Ltd, H2 2020
  • Urinary Incontinence - Pipeline by Cook MyoSite Inc, H2 2020
  • Urinary Incontinence - Pipeline by Crystec Ltd, H2 2020
  • Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H2 2020
  • Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2020
  • Urinary Incontinence - Pipeline by Ixaltis, H2 2020
  • Urinary Incontinence - Pipeline by Johnson & Johnson, H2 2020
  • Urinary Incontinence - Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, H2 2020
  • Urinary Incontinence - Pipeline by Outpost Medicine Ltd, H2 2020
  • Urinary Incontinence - Pipeline by Pfizer Inc, H2 2020
  • Urinary Incontinence - Pipeline by Profem GmbH, H2 2020
  • Urinary Incontinence - Pipeline by Revance Therapeutics Inc, H2 2020
  • Urinary Incontinence - Pipeline by Saniona AB, H2 2020
  • Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2020
  • Urinary Incontinence - Dormant Projects, H2 2020
  • Urinary Incontinence - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Urinary Incontinence - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Urinary Incontinence - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Urinary Incontinence, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020